MXPA02007942A - Derivados de pirrolopirimidinona, procesos de preparacion y uso. - Google Patents

Derivados de pirrolopirimidinona, procesos de preparacion y uso.

Info

Publication number
MXPA02007942A
MXPA02007942A MXPA02007942A MXPA02007942A MXPA02007942A MX PA02007942 A MXPA02007942 A MX PA02007942A MX PA02007942 A MXPA02007942 A MX PA02007942A MX PA02007942 A MXPA02007942 A MX PA02007942A MX PA02007942 A MXPA02007942 A MX PA02007942A
Authority
MX
Mexico
Prior art keywords
preparation
pyrrolopyrimidinone derivatives
pyrrolopyrimidinone
derivatives
intermediates
Prior art date
Application number
MXPA02007942A
Other languages
English (en)
Inventor
Hoon Cha
Original Assignee
Sk Chemicals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Chemicals Co Ltd filed Critical Sk Chemicals Co Ltd
Publication of MXPA02007942A publication Critical patent/MXPA02007942A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Abstract

La invencion se refiere a una serie de derivados de pirrolopirimidinona de formula (1 ), a los procesos para su preparacion, a los productos intermediarios que intervienen en su preparacion, a sus usos como agentes terapeuticos, y a las composiciones farmaceuticas que los contienen.
MXPA02007942A 2000-02-17 2001-02-15 Derivados de pirrolopirimidinona, procesos de preparacion y uso. MXPA02007942A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20000007625A KR100358083B1 (ko) 2000-02-17 2000-02-17 피롤로피리미디논 유도체와 이의 제조방법, 그리고 이의용도
PCT/KR2001/000227 WO2001060825A1 (en) 2000-02-17 2001-02-15 Pyrrolopyrimidinone derivatives, process of preparation and use

Publications (1)

Publication Number Publication Date
MXPA02007942A true MXPA02007942A (es) 2004-09-10

Family

ID=19647449

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02007942A MXPA02007942A (es) 2000-02-17 2001-02-15 Derivados de pirrolopirimidinona, procesos de preparacion y uso.

Country Status (23)

Country Link
US (1) US6962911B2 (es)
EP (1) EP1257553B1 (es)
JP (1) JP4845076B2 (es)
KR (1) KR100358083B1 (es)
CN (1) CN1312153C (es)
AT (1) ATE267829T1 (es)
AU (2) AU2001236140B9 (es)
BR (1) BRPI0108395B8 (es)
CA (1) CA2400268C (es)
DE (1) DE60103508T2 (es)
DK (1) DK1257553T3 (es)
ES (1) ES2222344T3 (es)
HU (1) HU230344B1 (es)
IL (2) IL151234A0 (es)
MX (1) MXPA02007942A (es)
NO (1) NO323553B1 (es)
NZ (1) NZ520842A (es)
PL (1) PL210796B1 (es)
PT (1) PT1257553E (es)
RU (1) RU2263676C2 (es)
TR (1) TR200402101T4 (es)
WO (1) WO2001060825A1 (es)
ZA (1) ZA200206587B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100358083B1 (ko) * 2000-02-17 2002-10-25 에스케이케미칼주식회사 피롤로피리미디논 유도체와 이의 제조방법, 그리고 이의용도
EP1362858A1 (en) * 2002-05-15 2003-11-19 SK Chemicals Co., Ltd. Pyrrolopyrimidinone derivates, process of preparation and use
DE10229778A1 (de) * 2002-07-03 2004-01-29 Bayer Ag Neue Verwendung von Imidazotriazinonen
FR2842809A1 (fr) * 2002-07-26 2004-01-30 Greenpharma Sas NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION
CN100374441C (zh) 2003-06-06 2008-03-12 天津倍方科技发展有限公司 二氢吡咯[2，3-d]嘧啶-4-酮衍生物，其制备方法及其制药用途
TW200745106A (en) * 2005-10-03 2007-12-16 Astrazeneca Ab Chemical compounds
AU2007270276A1 (en) * 2006-07-03 2008-01-10 Sk Chemicals Co., Ltd. Salts of pyrrolopyrimidinone derivatives and process for preparing the same
KR20080003599A (ko) * 2006-07-03 2008-01-08 에스케이케미칼주식회사 피롤로피리미디논 유도체의 겐티세이트 염 및 이의제조방법
KR101002490B1 (ko) * 2007-06-09 2010-12-17 동아제약주식회사 유데나필을 유효성분으로 함유하는 만성 심부전증 치료용약학적 조성물
AU2010306646B2 (en) 2009-10-16 2016-09-01 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
MY176900A (en) 2009-10-16 2020-08-26 Rib X Pharmaceuticals Inc Antimicrobial compounds and methods of making and using the same
EP2488532B1 (en) 2009-10-16 2018-05-09 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
JP2013523809A (ja) 2010-04-05 2013-06-17 エスケー ケミカルズ カンパニー リミテッド Ｐｄｅ５抑制剤を含む皮膚しわ改善用組成物
CN102372730B (zh) * 2010-08-19 2014-03-26 山东轩竹医药科技有限公司 桥环取代的磷酸二酯酶抑制剂
CN102134242B (zh) * 2011-01-21 2013-08-28 浙江大德药业集团有限公司 一种用于治疗阳痿的快速长效的化合物
TWI490220B (zh) * 2011-04-04 2015-07-01 Sk Chemicals Co Ltd 包含ｐｄｅ５抑制劑之用於減少皮膚皺紋之組成物
WO2012173689A2 (en) * 2011-04-15 2012-12-20 Rib-X Pharmaceuticals, Inc. Antimicrobial compounds and methods of making and using the same
CN103826638B (zh) 2011-09-09 2015-11-25 Sk化学公司 含有pde5 抑制剂的减少皮肤皱纹的组合物
EP3981409A1 (en) 2012-12-04 2022-04-13 Aribio Inc. Composition comprising phosphodiesterase type 5 inhibitor for inhibiting apoptosis of nerve cells
MX2016002975A (es) 2013-09-09 2016-10-21 Melinta Therapeutics Inc Compuestos antimicrobianos y métodos de fabricación y utilización de los mismos.
WO2015035421A1 (en) 2013-09-09 2015-03-12 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
MX2017011616A (es) 2015-03-11 2018-04-11 Melinta Therapeutics Inc Compuestos antimicrobianos y métodos para hacerlos y usarlos.
CN104744478B (zh) * 2015-03-20 2016-08-24 中国人民解放军第二军医大学 一种防治辐射损伤的化合物、单晶及其制备方法和应用
US10570137B2 (en) * 2015-11-16 2020-02-25 Topadur Pharma Ag 2-phenyl-3,4-dihydropyrrolo[2,1 -F] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof
BR112019024300A2 (pt) * 2017-05-22 2020-06-16 Topadur Pharma Ag Ativadores de guanilato ciclase solúvel com modo duplo de ação e inibidores da fosfodiesterase e usos dos mesmos
KR20210041596A (ko) 2018-08-06 2021-04-15 니콕스 에스아 산화질소 방출 포스포디에스테라제 타입 5 억제제
EP3887376A1 (en) 2018-11-28 2021-10-06 Topadur Pharma AG Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
KR102271305B1 (ko) 2020-05-21 2021-06-30 주식회사 아리바이오 치매 예방 및 치료용 조성물
WO2021245192A1 (en) 2020-06-04 2021-12-09 Topadur Pharma Ag Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
CN111825593B (zh) * 2020-08-19 2023-04-07 上海成澄科技有限公司 3-氨基吡咯-2-甲酰胺类化合物的合成方法
KR102272907B1 (ko) 2020-11-05 2021-07-05 주식회사 아리바이오 치매 예방 및 치료용 조성물
KR102272910B1 (ko) 2021-01-28 2021-07-06 주식회사 아리바이오 당뇨병을 동반한 치매 예방 및 치료용 조성물
KR20220140960A (ko) 2021-04-12 2022-10-19 주식회사 아리바이오 당뇨병을 동반한 치매 예방 및 치료용 조성물
KR20220146095A (ko) 2021-04-23 2022-11-01 주식회사 아리바이오 Pde5 억제제와 글루코코르티코이드 수용체 길항제 병용투여를 통한 치매 예방 및 치료용 조성물
KR102311224B1 (ko) 2021-04-23 2021-10-13 주식회사 아리바이오 Pde5 억제제와 글루코코르티코이드 수용체 길항제 병용투여를 통한 치매 예방 및 치료용 조성물
AU2022354094A1 (en) 2021-09-29 2024-02-15 Topadur Pharma Ag Topical compositions of 2-phenyl-3,4-dihydropyrrolo[2,l-f] [1,2,4]triazinone derivatives and uses thereof
KR20230129639A (ko) 2022-03-02 2023-09-11 연세대학교 산학협력단 이중작용 pde5 억제제/질산유기에스터의 국소 혈류 증진을 위한 경피 투약 형태
WO2023166013A1 (en) 2022-03-02 2023-09-07 Topadur Pharma Ag Topical compositions and uses therof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5761734B2 (es) * 1973-09-27 1982-12-25 Takeda Chemical Industries Ltd
JPS5761734A (en) * 1980-10-02 1982-04-14 Teijin Ltd Spun like fabric
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9311920D0 (en) * 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
JP3713783B2 (ja) * 1995-01-20 2005-11-09 大正製薬株式会社 １Ｈ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体
WO1998049166A1 (en) * 1997-04-25 1998-11-05 Pfizer Limited PYRAZOLOPYRIMIDINONES WHICH INHIBIT TYPE 5 CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE (cGMP PDE5) FOR THE TREATMENT OF SEXUAL DYSFUNCTION
JP3721077B2 (ja) * 1998-04-20 2005-11-30 ファイザー・インク 性的不全を治療するためのピラゾロピリミジノンｃＧＭＰＰＤＥ５阻害剤
KR100358083B1 (ko) * 2000-02-17 2002-10-25 에스케이케미칼주식회사 피롤로피리미디논 유도체와 이의 제조방법, 그리고 이의용도

Also Published As

Publication number Publication date
CA2400268C (en) 2009-08-18
US6962911B2 (en) 2005-11-08
ZA200206587B (en) 2003-10-09
NO323553B1 (no) 2007-06-11
DE60103508T2 (de) 2005-06-30
US20030171361A1 (en) 2003-09-11
AU2001236140B2 (en) 2006-01-12
RU2263676C2 (ru) 2005-11-10
BRPI0108395B8 (pt) 2021-05-25
KR100358083B1 (ko) 2002-10-25
EP1257553A1 (en) 2002-11-20
HUP0300527A2 (hu) 2003-07-28
DK1257553T3 (da) 2004-10-04
AU3614001A (en) 2001-08-27
HU230344B1 (hu) 2016-02-29
BR0108395A (pt) 2003-03-11
PT1257553E (pt) 2004-10-29
NO20023823L (no) 2002-10-09
DE60103508D1 (de) 2004-07-01
ATE267829T1 (de) 2004-06-15
CA2400268A1 (en) 2001-08-23
PL358188A1 (en) 2004-08-09
HUP0300527A3 (en) 2012-10-29
AU2001236140B9 (en) 2006-08-31
EP1257553B1 (en) 2004-05-26
BRPI0108395B1 (pt) 2017-06-06
NO20023823D0 (no) 2002-08-13
ES2222344T3 (es) 2005-02-01
CN1422271A (zh) 2003-06-04
WO2001060825A1 (en) 2001-08-23
IL151234A (en) 2010-05-17
TR200402101T4 (tr) 2004-10-21
IL151234A0 (en) 2003-04-10
JP2003523344A (ja) 2003-08-05
RU2002124872A (ru) 2004-01-10
NZ520842A (en) 2004-04-30
CN1312153C (zh) 2007-04-25
KR20010083637A (ko) 2001-09-01
JP4845076B2 (ja) 2011-12-28
PL210796B1 (pl) 2012-03-30

Similar Documents

Publication Publication Date Title
MXPA02007942A (es) Derivados de pirrolopirimidinona, procesos de preparacion y uso.
SE9904505D0 (sv) Novel compounds
GB0003154D0 (en) Novel compounds
PL358281A1 (en) Novel compounds
PL366198A1 (en) Novel compounds
MXPA04000577A (es) Derivados de dolastatina 10.
MXPA04000756A (es) Nuevos compuestos.
NZ284846A (en) 1-substituted-pyrazolo[3,4-b]pyridin-5-carboxylic acid derivatives, preparation, use, intermediates and pharmaceutical compositions thereof
IL145430A0 (en) N-cyanomethyl amides, processes for the preparation thereof and pharmaceutical compositions containing the same
DE60112609D1 (en) Pyrazolopyridine
MY133392A (en) Novel substituted pyrazole derivatives
MY136430A (en) N-adamantylmethyl derivatives, pharmaceutical compositions containing them and processes for their preparation
MXPA04000755A (es) Nuevos compuestos.
GB0004128D0 (en) Novel compounds
DE60112330D1 (en) Pyrazolopyridinderivate
PL364598A1 (en) Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments
MY135218A (en) 2,6-quinolinyl and 2,6-naphthyl derivatives and their use in the treatment of vla-4 dependent diseases
YU87202A (sh) Derivati arilmetilamina koji se koriste kao inhibitori triptaze
IL160171A0 (en) Depsipeptide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
MXPA02009643A (es) Sintesis acortada de derivados de 3,3-diarilpropilamina.
IL147149A0 (en) Novel diphenyl-piperidine derivate
RS19504A (en) Novel compounds and compositions as cathepsin inhibitors
EP1019047A4 (en) ANTITHROMBOTIC AGENTS
MXPA02012426A (es) Compuestos nuevos.
PL328225A1 (en) Diphenylstilbenes as pro-medications used to produce cox-2-inhibitors

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights
GD Licence granted